Hypoglycemic Therapy and the Course of Post-Covid Syndrome, is There a Connection?
Russian Archives of Internal Medicine
; 13(2):129-135, 2023.
Article
in English
| EMBASE | ID: covidwho-2315556
ABSTRACT
Diabetes mellitus (both type 1 and type 2) is considered one of the risk factors for severe COVID-19 and death from this infection. Past infection with COVID-19 leads to deterioration in the control of existing diabetes mellitus, progression of pre-diabetes to diabetes, an increase in the number of new cases of diabetes and an increase in the proportion of glucocorticoid-induced diabetes, which significantly aggravates the course of post-COVID syndrome for this category of patients. Antihyperglycemic drugs may influence the pathogenesis of COVID-19, which may be of relevance for the treatment of patients with type 2 diabetes mellitus and post-COVID syndrome. The review also presents our own data on the effect of various regimens of oral hypoglycemic agents on post-COVID syndrome in people with type 2 diabetes mellitus. The observation showed that the use of dipeptidyl peptidase-4 inhibitors as part of a treatment strategy in patients with type 2 diabetes mellitus with a past COVID-19 infection was associated with a decrease in the duration and severity of post-COVID symptoms.Copyright © 2023 The Russian Archives of Internal Medicine. All rights reserved.
COVID-19 infection; diabetes mellitus; dipeptidyl peptidase-4 inhibitors; metformin; post-COVID syndrome; adult; article; coronavirus disease 2019; drug therapy; human; long COVID; non insulin dependent diabetes mellitus; antidiabetic agent; dipeptidyl peptidase IV inhibitor; oral antidiabetic agent
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Topics:
Long Covid
Language:
English
Journal:
Russian Archives of Internal Medicine
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS